Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March

Rhea-AI Summary

Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has announced its participation in two major healthcare conferences in March 2025. The company will engage in analyst-led fireside chats at:

• The Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25AM ET
• The Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00AM ET

Both events will be accessible via live audio on the company's website investor.pacira.com under the 'Events' section. Webcasts will remain available for replay for two weeks following each event.

PARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

• Raymond James 46^th Annual Institutional Investors Conference on Wednesday, March 5^th at 10:25AM ET.
• Barclays 27^th Annual Global Healthcare Conference on Wednesday, March 12^th at 8:00AM ET.

Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

FAQ

When is Pacira BioSciences (PCRX) presenting at the Raymond James Conference in March 2025?

Pacira BioSciences will present at the Raymond James Conference on Wednesday, March 5th, 2025, at 10:25AM ET.

How can investors access PCRX's healthcare conference presentations in March 2025?

Investors can access live audio of the presentations through the 'Events' page on investor.pacira.com, with replays available for two weeks after each event.

What healthcare conferences will PCRX attend in March 2025?

PCRX will participate in the Raymond James 46th Annual Institutional Investors Conference and the Barclays 27th Annual Global Healthcare Conference.

When is Pacira BioSciences' presentation at the Barclays Healthcare Conference?

Pacira BioSciences will present at the Barclays Global Healthcare Conference on Wednesday, March 12th, 2025, at 8:00AM ET.